MAP2K7 and cancer: A previous study has suggested that cell lines harboring the KRAS mutation such as HCT116 as well as the BRAF mutation are likely to be sensitive to CH5126766 [18], whereas RAS-mutant cancer cells may not be sensitive to other MEK inhibitors.